Pharvaris (PHVS) Cantor Global Healthcare Conference 2025 summary

Company overview and development pipeline

• Late-stage pre-commercial biotech developing a single active ingredient for both treatment and prevention of bradykinin-mediated attacks.

• Anticipates key data readouts in Q4 this year and another phase III readout in the second half of next year.

• Plans to file for approval in the US in the first half of 2026, targeting a launch in early 2027.

• Preparing for commercial launch by expanding the organization and building relationships with key stakeholders.

• Considering partnerships for ex-US commercialization due to pricing and market access challenges.

Product positioning and market landscape

• Deucrictibant aims to be a leading oral therapy for both on-demand and prophylactic use in HAE, with injectable-like efficacy and placebo-like safety.

• Oral therapies are expected to become the dominant first-line option for prophylaxis, with a significant share of new patients already choosing oral options.

• The product targets four key market segments: new prophylaxis patients, patients who discontinued other oral therapies, current oral users, and injectable users.

• Anticipates that oral therapies could capture 50–60% of the total market over time.

• The ability to offer both on-demand and prophylactic oral therapy is seen as a major differentiator.

Clinical development and trial design

• Phase III on-demand trial aims to confirm rapid onset of symptom relief (within 15–30 minutes) and complete resolution within 12 hours, with over 85% of attacks resolved with a single dose.

• Trial design includes intensive assessment with 25 time points in 24 hours to capture efficacy endpoints.

• Extended-release formulation for prophylaxis is expected to improve safety and efficacy, with higher and more persistent trough levels.

• Real-world use in acquired angioedema patients supports confidence in the extended-release formulation.

• Innovative endpoints, such as end of progression, are included to demonstrate rapid action.